Specific subcutaneous immunotherapy with recombinant grass pollen allergens: First randomized dose-ranging safety study

Clinical and Experimental Allergy

Volumn 42, Issue 6, 2012, Pages 936-945

  Klimek, L ^a   Schendzielorz, P ^a,b   Pinol, R ^a   Pfaar, O ^a  

^a Center for Rhinology and Allergology   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Allergy; Dose ranging safty study; Phleum pratense; Recombinant allergens; Subcutaneous immunotherapy

Indexed keywords

ALUMINUM HYDROXIDE; GRASS POLLEN EXTRACT; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; PLACEBO; RECOMBINANT ALLERGEN;

ADULT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; BRONCHOSPASM; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DISEASE CLASSIFICATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DYSPNEA; EYE SWELLING; FATIGUE; FEMALE; FLUSHING; GRASS POLLEN; HEADACHE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MALE; PHLEUM PRATENSE; PRIORITY JOURNAL; PROVOCATION TEST; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUBCUTANEOUS IMMUNOTHERAPY; SWELLING; URTICARIA;

ADULT; ALLERGENS; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MALE; PHLEUM; POLLEN; RECOMBINANT PROTEINS; RHINITIS, ALLERGIC, SEASONAL; TREATMENT OUTCOME;

EID: 84865175753     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2012.03971.x     Document Type: Article

References (36)

1. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004; 24:758-64.
2. Bousquet J, Van CP, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108:S147- 334.
3. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102:558-62.
4. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007: CD001936.
5. Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468-75.
6. Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002; 57:306-12.
7. Moller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:251-6.
8. Pajno GB, Barberio G, De LF, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31:1392-7.
9. Valenta R, Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol 2007; 119: 826-30.
10. Cromwell O, Fiebig H, Suck R et al. Strategies for recombinant allergen vaccines and fruitful results from first clinical studies. Immunol Allergy Clin North Am 2006; 26:261-81.
11. Vrtala S. From allergen genes to new forms of allergy diagnosis and treatment. Allergy 2008; 63:299-309.
12. Andersson K, Lidholm J. Characteristics and immunobiology of grass pollen allergens. Int Arch Allergy Immunol 2003; 130:87-107.
13. van Ree R., van Leeuwen WA, Aalberse RC. How far can we simplify in vitro diagnostics for grass pollen allergy?: a study with 17 whole pollen extracts and purified natural and recombinant major allergens. J Allergy Clin Immunol 1998; 102:184-90.
14. Suphioglu C. What are the important allergens in grass pollen that are linked to human allergic disease? Clin Exp Allergy 2000; 30:1335-41.
15. Matthiesen F, Lowenstein H. Group V allergens in grass pollens. II. Investigation of group V allergens in pollens from 10 grasses. Clin Exp Allergy 1991; 21:309-20.
16. Moingeon P, Hrabina M, Bergmann KC et al. Specific immunotherapy for common grass pollen allergies: pertinence of a five grass pollen vaccine. Int Arch Allergy Immunol 2008; 146:338-42.
17. Westritschnig K, Horak F, Swoboda I et al. Different allergenic activity of grass pollen allergens revealed by skin testing. Eur J Clin Invest 2008; 38: 260-7.
18. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005; 116:608-13.
19. European Medicines Agency (EMEA). Committee for Medicinal Products of Human Use (CHMP) and Efficacy Working Party (EWP): Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. European Medicines Agency CHMP/EWP/ 18504/2006. 2008.
20. Tryba M, Ahnefled F, Barth J et al. Akkuttherpie anaphylakter Reaktionen. Ergebnis einer interdisziplinären Konsensuskonferenz. Allergo J 1994; 3: 211-24.
21. Cromwell O, Suck R, Kahlert H, Nandy A, Weber B, Fiebig H. Transition of recombinant allergens from bench to clinical application. Methods 2004; 32:300-12.
22. van Ree R., Chapman MD, Ferreira F et al. The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy 2008; 63:310-26.
23. Ventura MT, Giuliano G, Buquicchio R, Accettura F, Carbonara M. Local and systemic reactions occurring during immunotherapy: an epidemiological evaluation and a prospective safetymonitoring study. Immunopharmacol Immunotoxicol 2008; 30:153-61.
24. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy 2006; 61(Suppl 82):1-20.
25. Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117:319-25.
26. Mellerup MT, Hahn GW, Poulsen LK, Malling H. Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy 2000; 30:1423-9.
27. Rogala B, Gluck J. Risks and benefits of allergen immunotherapy. Expert Opin Drug Saf 2009; 8:253-6.
28. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy 2005; 60:801-7.
29. Roberts G, Hurley C, Turcanu V, Lack G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol 2006; 117:263-8.
30. Francis JN, James LK, Paraskevopoulos G et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008; 121:1120-5.
31. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007; 119:780- 91.
32. Wachholz PA, Soni NK, Till SJ, Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003; 112:915- 22.
33. Hardy CL, Rolland JM, O'Hehir RE. Blocking antibodies in allergen immunotherapy: the Yin and Yang. Clin Exp Allergy 2004; 34:510-2.
34. Nouri-Aria KT, Wachholz PA, Francis JN et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004; 172:3252-9.
35. Leynadier F, Banoun L, Dollois B et al. Immunotherapy with a calcium phosphate-adsorbed five-grass-pollen extract in seasonal rhinoconjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy 2001; 31:988- 96.
36. Walker SM, Varney VA, Gaga M, Jacobson MR, Durham SR. Grass pollen immunotherapy: efficacy and safety during a 4-year follow-up study. Allergy 1995; 50:405-13.